# EDGAR Filing Document

**Accession Number:** 0001816815
**File Stem:** 0001641172-25-026939
**Filing Date:** 2025-9
**Character Count:** 17448
**Document Hash:** 6b620dbc32d4a63fe0fb1a2f0adc4287
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026939.hdr.sgml**: 20250909

**ACCESSION NUMBER**: 0001641172-25-026939

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250909

**FILED AS OF DATE**: 20250909

**DATE AS OF CHANGE**: 20250909

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bon Natural Life Ltd
- **CENTRAL INDEX KEY:** 0001816815
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40517
- **FILM NUMBER:** 251301770

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 601, BLOCK C, GAZELLE VALLEY, NO.69
- **STREET 2:** JINYE ROAD, HIGH-TECH ZONE, XIAN
- **CITY:** SHAANXI
- **STATE:** F4
- **ZIP:** 710076
- **BUSINESS PHONE:** 0086-29-88346301

**MAIL ADDRESS:**
- **STREET 1:** ROOM 601, BLOCK C, GAZELLE VALLEY, NO.69
- **STREET 2:** JINYE ROAD, HIGH-TECH ZONE, XIAN
- **CITY:** SHAANXI
- **STATE:** F4
- **ZIP:** 710076

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2025**

**Commission File Number 001-40517**

**BON NATURAL LIFE LIMITED**

(Translation of registrant's name into English)

**Room 601, Block C, Gazelle Valley, No.69, Jinye Road**

**High-Tech Zone, Xi'an, Shaanxi, China**

**People's Republic of China**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**Supply Agreement**

On September 1, 2025, our subsidiary Xi'an App-Chem Bio (Tech) Co., Ltd ("App-Chem") entered into a Sales Cooperation Agreement (the "Agreement") with Beijing Huahai Keyuan Technology Co., Ltd ("Huahai Keyuan"). Under the Agreement, App-Chem grants Huahai Keyuan the non-exclusive right to market, distribute and sell App-Chem's second-generation Apple Series Products, a line of natural weight management and metabolic health products formulated with apple polyphenols and plant proteins (collectively, the "Products") in the Chinese market. The term of the Agreement is twenty-four (24) months.

App-Chem will be responsible for all research and development, production and quality control such that the Products are compliant with applicable national standards.

Pursuant to the Agreement Huahai Keyuan has guaranteed aggregate sales of no less than US$18,000,000 over the term.

In the event the Products fail to conform to the agreed quality standards, App-Chem shall be responsible for all testing expenses, as well as any costs associated with returns and exchanges.

Products will be transported to such sites as designated by Huahai Keyuan.

App-Chem must receive full payment from Huahai Keyuan for any Products before they are dispatched.

If either party breaches the Agreement and fails to cure such breach within thirty (30) working days after receipt of written notice from the non-breaching party, the non-breaching party may terminate the Agreement. The Agreement may also be terminated at any time by the mutual written consent of both parties. Either party that terminates the Agreement without justifiable reasons (as defined in the Agreement) or fails to fulfill its obligations under the Agreement shall compensate the other party with a liquidated damages equivalent to 15% of the total Agreement amount. Any lawsuits must be filed in a court located in the People's Republic of China.

The foregoing is a summary of the material terms of the Agreement. The Agreement contains additional terms, covenants and conditions and should be reviewed in its entirety for additional information.

**Exhibits**

The following exhibits are included in this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 10.1 | [Translation of Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd.](ex10-1.htm) |
| 99.1 | [Press Release dated September 9, 2025](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 9, 2025 | **Bon Natural Life Limited** | **Bon Natural Life Limited** |
|  | By: | */s/ Yongwei Hu* |
|  |  | Yongwei Hu |
|  |  | Chairman and Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**Xi'an App-Chem Bio (Tech) and Beijing Huahai Keyuan**

**Sales Cooperation Agreement for Second-Generation Apple Polyphenol Products**

Party A: Xi'an App-Chem Bio (Tech) Co., Ltd. Date: 20250901 Place:XI'AN <br> Party B: Beijing Huahai Keyuan Technology Co., Ltd. Agreement No.: BONHHKY20250901

Xi'an App-Chem Bio(Tech) Co., Ltd. (NASDAQ: BON, "Party A") is a supplier of natural health bioactive ingredients and health solutions. Party A specializes in the research, development, production, and sales of natural active ingredients, with a focus on the study and development of ingredients for personal health and care products. It is a globally leading supplier of apple polyphenol series products. Party A's apple polyphenol series products are widely sold in China, Japan, South Korea, the United States, the European Union, and other countries and regions, known for their excellent quality and strong reputation.

Party B is a leading domestic health company headquartered in Beijing, possessing professional brand management and marketing with experienced health consulting team. Party B specializes in the market development of original health products and demonstrates proven expertise in market expansion and brand building capabilities in this field.

Leveraging cutting-edge low-temperature extraction technology, BON's second-generation Apple Series delivers significantly higher bioactivity than its predecessor through enhanced active ingredient extraction efficiency. This technological breakthrough enables the development of a proprietary formulation combining apple polyphenols with stronger activity and plant protein, demonstrating exceptional efficacy in weight management and metabolic health applications. Also, this innovation perfectly positioning the product at the intersection of validated market needs and innovative functionality with exceptional growth potential.

After friendly consultations between Party A and Party B, the following cooperation agreement is hereby reached regarding Party B's distribution of Party A's second-generation Apple Series Products in the Greater China market.

I. **Main Matters of the Agreement**

1．Party A hereby grants Party B the non-exclusive priority distribution rights to its second-generation Apple Series Products in the Greater China market for a period of twenty-four (24) months after the signing of this agreement.

2．Party B agrees to accept the non-exclusive priority distribution rights for Party A's second-generation Apple Series Products in the Greater China market, valid for a period of twenty-four (24) months from the date of signing this Agreement.

3．Party A shall be responsible for product research, development, and manufacturing, and shall supply products to Party B. Party A shall ensure consistent and reliable supply of products, as well as continuous and rapid innovation, iteration and upgrading. The products include a series of natural weight management and metabolic health products with a compound formula centered on "apple polyphenols + plant protein."

4．Party B shall be responsible for the sales of the series of the Products under this category in the Greater China market during the term of this agreement. Party B undertakes that the total sales revenue of the said Product shall be no less than US$18,000,000 during such period.

5．Both parties agree that during the specific business advancement, they may enter into business agreements on product categories, market arrangements, product development and other matters, which shall constitute an integral part of this agreement.

II. **Cooperation Period.** Term of this agreement should be twenty-four (24) months from the date of signing herein.

III. **Payment.** Party B shall prepay the full amount for the goods prior to shipment, and Party A shall deliver the goods only upon receipt of the full payment.

IV. **Delivery and Location.** Under this agreement, Party B shall periodically and in batches provide shipping documents to Party A, whereupon Party A shall deliver the goods as agreed. The goods shall be delivered to the address in China designated by Party B.

**V. Responsibilities and Obligations.**

1．Party B guarantees that all sales activities shall comply with relevant laws and regulations and shall not engage in illegal sales during the sales process.

2．Party B shall effect payment on time as stipulated in the agreement. Should Party A's failure to deliver the goods on schedule result from Party B's delayed payment or other attributable causes, the delivery date shall be postponed, and Party A shall not bear the liability for breach of agreement

3．Party A shall deliver the goods on time as required by Party B and ensure that the packaging of the goods meets the requirements of logistics transportation

4．In the event that the Product quality fails to conform to the agreed standards, Party A shall bear all the testing fees and the costs of returns and exchanges.

5．If either party fails to perform this agreement without due cause or unilaterally terminates this agreement without authorization, such Party shall be liable to pay the other party a penalty of 15% of the total price of this agreement. Should partial non-performance of this Agreement occur due to a Party's attributable default, the defaulting Party shall pay the other party a penalty of 10% of the total price of the unperformed part of this agreement.

VI. **Force Majeure.** Both Parties shall strictly fulfill their respective responsibilities and obligations hereunder. In the event that performance becomes impossible or delayed due to Force Majeure, the Parties shall negotiate in good faith to reach a mutually agreed solution.

VII. **Termination of the Agreement.** If one party violates the agreement and fails to make corrections within thirty (30) working days after receipt of written demand from the non-violating party, the non-violating party shall have the right to terminate this agreement. In addition, this agreement may be terminated by mutual consent of both parties.

VIII. **Miscellaneous**. If there are any matters not covered herein, both parties shall resolve them through friendly consultation and may enter into a separate agreement to stipulate them.

IX. **Legal jurisdiction.** In the event of any dispute arising during the execution of this contract, if no agreement can be reached through consultation, the dispute shall be settled through litigation and the People's Court where Party A is located shall have jurisdiction.

X. This agreement shall come into effect upon signatures and seals by both parties. It is executed in quadruplicate, with each party holding two copies, all of which have the same validity.

---

| | |
|:---|:---|
| **Party A:** Xi'an App-Chem Bio (Tech) Co., Ltd.<br>| **Party B:** Beijing Huahai Keyuan Technology Co., LTD |
| **Seal:** | **Seal:** |
| **Representative (Signature) :** | **Representative (Signature) :** |
| September 1, 2025 | September 1, 2025 |

---

## Exhibit 99.1

**Exhibit 99.1**

**BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products**

XI'AN, China, Sep 9, 2025 (PR NEWSWIRE) - Bon Natural Life Limited (NASDAQ: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 24 months with a total contract value of US$18 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's innovative second-generation Apple Series health products across Greater China, tapping into significant market potential in the weight management and metabolic health sectors.

Leveraging advanced low-temperature extraction technology, BON's second-generation Apple Series delivers 80% higher bioactivity than its predecessor by improving the efficiency of the active ingredient extraction. This technological allows for a proprietary formulation that combines highly active apple polyphenols with plant protein, demonstrating strong efficacy in weight management and metabolic health applications.

After decades of evolution, protein supplements have become mainstream health essentials, integral to fitness regimens, immune support programs, and longevity-focused nutrition plans. BON's innovative incorporation of apple polyphenols into protein supplements delivers clinically validated benefits, including improved lipid metabolism, enhanced body composition, and reduced of age-related muscle loss - positioning the product at the intersection of established market needs and innovative functionality with significant growth potential.

Early market validation is encouraging, with comparable apple polyphenol blends generating over $40 million in monthly sales. Industry analysts attribute this to consumers' growing willingness to pay for scientifically validated "nutraceutical products." BON management expressed confidence in achieving strong market performance given the competitive advantages of its second-generation formulation.

"We have both the responsibility and capability as a global leader in apple polyphenols to develop superior health solutions," stated Mr. Yongwei Hu, Chairman and CEO of BON. "Through our vertically integrated supply chain - from raw materials to production - we are well-positioned to lead the rapidly growing metabolic health segment. The enhanced bioactivity of our second-generation apple polyphenols is expected to drive significant revenue and profit growth across nutraceutical and functional food markets, enhancing shareholder value and delivering strong returns."

**About Bon Natural Life Limited ("BON")**

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu \| IR

Email: bonnatural@appchem.cn

**Safe Harbor Statement**

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.